Table 3.

AEs related to eribulin occurring in two or more patients

AEEribulin mesylate initial dose level (mg/m2)
0.25 (n = 1)0.5 (n = 4)1 (n = 3)2 (n = 7)2.8 (n = 3)4 (n = 3)
Grade 1/2Grade 3/4Grade 1/2Grade 3/4Grade 1/2Grade 3/4Grade 1/2Grade 3/4Grade 1/2Grade 3/4Grade 1/2Grade 3/4
Blood and lymphatic system disorders
    Anemia001 (25)01 (33)01 (14)01 (33)01 (33)0
    Febrile neutropenia00000001 (14)02 (67)03 (100)
    Neutropenia000001 (33)*1 (14)4 (57)01 (33)01 (33)
    Leukopenia000001 (33)*1 (14)001 (33)*1 (5)3 (14)
    Thrombocytopenia00001 (33)000001 (33)0
Gastrointestinal disorders
    Constipation0000001 (14)0001 (33)0
    Dry mouth00001 (33)01 (14)00000
    Nausea002 (50)00000002 (67)0
    Vomiting00000000002 (67)0
Metabolism and nutrition disorders
    Anorexia001 (25)0002 (29)00000
    Decreased appetite001 (25)01 (33)0001 (33)000
General disorders and administration site conditions
    Fatigue002 (50)0002 (29)02 (67)01 (33)0
    Pyrexia0000001 (14)0001 (33)0
Laboratory investigations
    Alanine amino-transferase increases003 (75)000000000
    Alkaline phosphatase increases002 (50)000000000
    Weight decreases001 (25)01 (33)0000000
Respiratory, thoracic, and mediastinal disorders
    Cough0000001 (14)0001 (33)0
Skin and subcutaneous tissue disorders
    Alopecia0000003 (43)01 (33)03 (100)0
    Pruritic rash0000001 (14)01 (33)000
Vascular disorders
    Hypotension001 (25)00000001 (33)0
  • * No grade 4 events.